Article Text

Download PDFPDF
1008 Risk-reducing surgery (RRS) in hereditary breast and ovarian cancer syndrome (HBOS): retrospective monocentric study
  1. Hanna Trukhan1,
  2. Sergey Mavrichev2,
  3. Alena Dalamanava2,
  4. Sergey Taranenko2,
  5. Oleg Akinfeev2,
  6. Alena Bolshakova2,
  7. Dmitry Dyatko2,
  8. Dmitry Rovski2 and
  9. Irina Bakinovskaya2
  1. 1Belarussian Medical Academy of postgraduate Education, Minsk, Belarus
  2. 2N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus


Introduction/Background Pathogenic variants of BRCA1 and BRCA2 result in hereditary breast-ovarian cancer syndrome (HBOS) in affected persons. RRS included risk-reducing mastectomy (RRM) and risk-reducing salpingoophorectomy (RRSO). We aimed to analyze patients with BRCA mutations in a single center experience.

Methodology RRS was performed in all patients carrying BRCA1 (aged between 25–52 years) referred at N.N. Alexandrov National Cancer Centre of Belarus from 2020 till now. Fifty-three percent of the patient population had previous history of breast cancer or ovarian cancer.

Results Thirty patients underwent RRS for their BRCA1/2 mutations. In our study was reveled only BRCA1 mutation. Our patients were divided in 3 groups. 1st - clinically healthy women, who carriers of BRCA 1 mutations (n=14), median age was 38 years. 9 patients underwent prophylactic subcutaneous mastectomy, 3 – prophylactic hysterectomy with bilateral salpingo-ophrectomy, 4 - only bilateral salpingo-ophrectomy. At the same time, two patients underwent both surgical prophylaxis of breast cancer and prophylaxis of ovarian cancer. In the 2nd group - 4 patients with a history of ovarian cancer - underwent prophylactic subcutaneous mastectomy, median age was 45 years. In the 3rd group - 12 patients with a previously established diagnosis of breast cancer underwent prophylactic hysterectomy with bilateral salpingo-ophrectomy, median age was 45 years. In 100% of cases we used laparoscopic minimally invasive approach. Fallopian tubes were carried out according by See-FIM protocol. There was no serous tubular intraepithelial carcinoma detected during this time.

Conclusion RRS is safe and feasible in BRCA mutation carriers. It`s an important part of management prevention of HBOS.

Disclosures No disclosures.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.